Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Retinal Vein Occlusion Therapeutics Market Go Advanced and Next Generation  Spaceflight News

Global Retinal Vein Occlusion Therapeutics Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the ...

RVO patients at risk for loss to follow-up after anti-VEGF treatment  Healio

Ocular Surgery News | Despite the proven benefits of anti-VEGF injections for patients with retinal vein occlusion, a retrospective review of billing codes showed ...

Retinal Vein Occlusion Therapeutics Market Global Insights 2019- 2025 by Players: Acucela Inc, Addmedica SAS  The Market-News 24

Retinal Vein Occlusion Therapeutics Market Report fulfill the Current as well as Future aspects and trends. The market study on Global Retinal Vein Occlusion ...

FDA Approves Aflibercept Injection Treatment for Retinal Conditions  MD Magazine

The new FDA approval allows physicians to administer EYLEA in a prefilled syringe to treat retinal conditions with fewer preparation steps than vials.

Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the ASR  BioSpace

Published: Jul 27, 2019. Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic intravitreal drugs; KSI-301 continues ...

Prevalence of resolved paracentral acute middle maculopathy lesions in fellow eyes of patients with unilateral retinal vein occlusion  MD Linx

In this case-control observational study, researchers examined the prevalence of resolved paracentral acute middle maculopathy (PAMM) lesions in fellow eyes ...

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021  Spaceflight News

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021 | The Premier Source of Space Exploration and ...

Global Retinal Vein Occlusion Therapeutics Market Insights 2019- 2025 by Players: Acucela Inc, Addmedica SAS  The Industry News Room

Retinal Vein Occlusion Therapeutics Market Report fulfill the Current as well as Future aspects and trends. The market study on Global Retinal Vein Occlusion ...

Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe  Yahoo Finance

Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More  Yahoo Finance

It was a busy week for the biotech sector after the second-quarter earnings with collaborations and pipeline updates taking center stage. While Amgen AMGN ...

Retinal Vein Occlusion Therapeutics Market Size, Share, Growth, Trends, and Forecast, 2019 to 2023  Rapid News Network

Global Retinal Vein Occlusion Therapeutics Market Report 2019 – Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the ...

Global Retinal Vein Occlusion Therapeutics Market Insights Report 2019 – 2025 : Acucela Inc, Addmedica SAS – Island Daily Tribune  island Daily Tribune

The Global Retinal Vein Occlusion Therapeutics Market report elaborates the Retinal Vein Occlusion Therapeutics Industry overview. Various definitions and ...

Interesting Sessions to Come at ASRS 2019  MD Magazine

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article; Related *content*; Metrics; Responses ...

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Last trial OKed for Eylea to prevent blindness in premature infants  Korea Biomedical Review

The Korean drug regulator has approved a phase-3 clinical trial on Eylea (ingredient: aflibercept), an anti-vascular endothelial growth factor (anti-VEGF) ...

Retinal Vein Occlusion Market Size and Forecasts Research Report 2019  Industry Stats News

Retinal Vein Occlusion Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

FDA Action Alert: Regeneron, Kala and Vanda  BioSpace

Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2019 results on Jul 6, before the opening bell. In the last reported quarter, the ...

Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting  BioSpace

Published: Jul 24, 2019. Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented. PALO ALTO, Calif., July 24, 2019 /PRNewswire/ ...

Global Retinal Vein Occlusion Therapeutics Market 2019 Key Companies – Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Rise Media

Global Retinal Vein Occlusion Therapeutics Market Research Report 2019 overview: This report studies the Retinal Vein Occlusion Therapeutics market status ...

Use of topical bromfenac for treating ocular pain and inflammation bey | OPTH  Dove Medical Press

Barry A Schechter Cornea and Cataract *Service*, Florida Eye Microsurgical Institute, Boynton Beach, FL, USA Abstract: Topical ophthalmic nonsteroidal ...

Retinal Disease Therapeutics Market Increase CAGR at 8.6%, Analysis, Revenue, Growth Rate Forecast till 2026  Ghanasoccernet.com

The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and ...

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, ...

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance  Yahoo Finance

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger  Healio

From Retina *Service*, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania (XG, AO, CMA, FSA, JFV, JH, ACH);and ...

Retinal Vein Occlusion Market Opportunity, Growth, Share, Demand, Innovation, Top Companies – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  News Exterior

Retinal Vein Occlusion Market report offers a comprehensive valuation of the marketplace. It does so via in-depth comprehensions, grateful market growth by ...

JAK1 Filgotinib Promising for Rheumatoid Arthritis  Rheumatology Network

The JAK1 inhibitor filgotinib has been shown to be effective in rheumatoid arthritis patients who failed previous treatment with one or more biologic DMARD.

Kodiak Sciences Receives Positive Phase I Data  Contract Pharma

Kodiak Sciences Inc. achieved positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer ...

Retinal Vein Occlusion Therapeutics Market 2025 Analysis, Industry Top Manufactures, Market Size, Industry Growth  The Jеnnеr Nеws

Global “Retinal Vein Occlusion Therapeutics Market” provides complete attention on major industry drivers, opportunities, challenges, and their impact on market ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Global Retinal Vein Occlusion Market – Premium Insight, Industry Trends, Market Sizing & Forecasts to 2023  Technology Market

Introduction. Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

Retinal Vein Occlusion Therapeutics Market 2019 Business Insights,Top Companies,Growth, Market Size Global Market Share, Trends, Outlook, Opportunity and Demand Analysis, Forecast upto 2025  Independent Telegraph

Global “Retinal Vein Occlusion Therapeutics Market” research report covers the analysis about business overview, market size, share, trends, gross margin, ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.6% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 19 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Recon: Pfizer to Merge Off-Patent Drug Business With Mylan  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Pfizer to Merge Its Off-Patent Drug Unit With Mylan ...

Filgotinib Effective in RA Patients When bDMARDs Fail  DocWire News

Patients with active rheumatoid arthritis (RA) who are nonresponsive or intolerant to biologic disease-modifying antirheumatic drug (bDMARD) therapy may ...

Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial  MD Linx

Via a randomized clinical trial of 448 subjects with active rheumatoid arthritis (RA) who had an incomplete response or intolerance to 1 or more biologic ...

Filgotinib improves RA signs, symptoms in DMARD-refractory patients  Healio

Patients with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving ...

Global Retinal Vein Occlusion Market Business Analysis, Growth Rate, Trends, Forecast 2024  Financial Planning

Global Retropharyngeal Abscess Market 2019 report is the comprehensive study of current and future market analysis, trends & growth factors. This report also ...

Global Retinal Vein Occlusion Market 2019 Industry Size, Emerging Technologies, Future Demands, Opportunities, Regional Trends and Industry Growth by Forecast 2023  News In Bites

Global “Retinal Vein Occlusion Market” 2019 Research report provides information regarding market size, share, trends, growth, cost structure, key drivers and ...

Combined central retinal vein, central retinal artery and cilioretinal | IMCRJ  Dove Medical Press

Combined central retinal vein, central retinal artery and cilioretinal artery occlusion with ischemic macular hole secondary to severe orbital cellulitis after black fly ...

Retinal Vein Occlusion Market Global Research and Clinical Survey Report 2019 to 2025  Market Research Headlines

Global Retinal Vein Occlusion Market Size, Status And Forecast 2019-2025 report studies the most recent business trends, market development aspects, market ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

FDA Adds Warning for Higher Dose of Tofacitinib; Researchers Report on Another JAK Inhibitor  The Center for Biosimilars

The FDA Friday issued a black box warning for the 10-mg, twice-daily dose of tofacitinib, sold under the names Xeljanz or Xeljanz XR; the drug is an oral, ...

Global Retinal Vein Occlusion Therapeutics Market 2019 – Sanofi Aventis, Valeant Pharmaceuticals, Allergan, … – Honest News 24  Honest News 24

Global Retinal Vein Occlusion Therapeutics Market research report covers the analysis about business overview, market size, share, trends, gross margin, ...

Global Retinal Vein Occlusion Therapeutics Market Deep Analysis 2019-2026: Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  News Stock Exchange

The “Retinal Vein Occlusion Therapeutics Market” report is a profound study conducted based on the global market, which examines the ruthless structure of the ...

Rheumatoid Arthritis Therapeutics Market to Reach US$ 33,958.4 Mn by 2025, Introducing Cost-efficient Drugs Will Boost Market, says Fortune Business Insights  GlobeNewswire

Pune, July 30, 2019 (GLOBE NEWSWIRE) -- Exhibiting a high prevalence for rheumatoid arthritis, North America is forecast to lead the global Rheumatoid ...

Macular Edema Treatment Market Growth Till, 2018-2026: Coherent Market Insights  Business Intelligence

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an ...

Global Retinal Vein Occlusion Market 2019 – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  Biz Trends 24

The Retinal Vein Occlusion Market report presents key information on the market status of the key players and is a precious source of direct and plan for ...

Novel Pipeline Drugs for Intraocular Medication to Account for Substantial Impinge on the Global Intravitreal (IVT) Injectables Market Functioning  NewsVarsity

An Intravitreal (IVT) Injectables is an efficient way of treatment utilized in the administration of retinal ailments, for instance, retinal vein occlusion, macular ...

Global Retinal Vein Occlusion Drug Market By Competitive & Comparative Analysis till 2025  Market Research Gazette

The Retinal Vein Occlusion Drug market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, ...

Retinal Vein Occlusion Therapeutics Market with Key Players, Overview Regional, Consumers & Buyers Analysis 2024  The Inherent News

Global “Retinal Vein Occlusion Therapeutics Market Report 2019” gives a clear understanding of the current market situation which includes of antique and ...

Botulinum Toxin Market to Rise Impressively at 8.0% CAGR, Huons' Latest Launch of Botulinum Toxin Products to Enable Market Growth, says Fortune Business Insights  GlobeNewswire

Pune, Aug. 01, 2019 (GLOBE NEWSWIRE) -- The global Botulinum Toxin Market will witness considerable growth in the coming years due to the inflating ...

Specialist shares key messages of Euretina guidelines for management of RVO  Healio

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, ...

Global Retinal Vein Occlusion Therapeutics Market Report: Expected To Demand Drivers, Size And Progress Stimulators Expected To Growth During The Forecast Period 2019-2024  Market Reporter

Global “Retinal Vein Occlusion Therapeutics Market” Research Report 2019-2024 introduces a detailed research study to highlight opportunities, estimate the ...

Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint  GlobeNewswire

Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 -. - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week ...

Avastin as effective as Eylea for treating central retinal vein occlusion  EurekAlert

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Retinal Vein Occlusion Market Industry Size, CAGR Status, Geographical Segmentation, Drivers, Challenges, Trends Forecasts by 2025  Bridgeport Daily

Global “Retinal Vein Occlusion Market” report provides emerging opportunities in the market and the future impact of major drivers and challenges and, supports ...

Rising Prevalence of Retinal Diseases Will Support the Growth of Intravitreal (IVT) Injectables Market  Herald Space

Rising Prevalence of Retinal Diseases Will Support the Growth of Intravitreal (IVT) Injectables Market. Vitreo-retinal disease has been a major cause of ...

Global Retinal Vein Occlusion Treatment Market 2019-2023| Strong Pipeline and Recent Drug Approvals to Boost Demand | Technavio  Business Wire

The global retinal vein occlusion treatment market 2019-2023 is expected to post a CAGR of over 9% during the forecast period, according to Technavio.

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Global Retinal Vein Occlusion Therapeutics Market 2019 - Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB, Chengdu Kanghong Pharmaceuticals Group Co Ltd Business Pulze  Business Pulze

The Global Retinal Vein Occlusion Therapeutics Market report keenly analyzes significant features in major developing markets. The analysis includes market ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Sold by Hussman Strategic Advisors Inc.  Mayfield Recorder

Hussman Strategic Advisors Inc. trimmed its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 33.3% in the 2nd quarter, according to ...

Ocular Diagnostic Agents Market Poised to Garner Maximum Revenues by 2026  PortNews24

Eye is the most accessible organ in the human body. Due to this feature, ophthalmic diagnostics agents play a significant role in ophthalmology to aid effective ...

Treat-and-extend regimen reduces injection burden in macular edema secondary to CRVO  Healio

VIENNA — Intravitreal aflibercept injection with an individualized treat-and-extend schedule is a positive approach to macular edema secondary to central ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVES:Several imaging modalities have been developed to characterize ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Retinal Vascular Occlusion (RVO) Market Overview 2019, Global Industry Size, Share, SWOT Analysis, Technology Advancement, Competitive landscape, Regional Forecast to 2023 |  Medgadget

Retinal Vascular Occlusion (RVO) Market Overview Retinal disease burden has continued to rise worldwide, more so among the geriatric population. Many of.

Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript  Motley Fool

REGN earnings call for the period ending June 30, 2019.

Anti-VEGF Therapy for Retinal Vein Occlusions  Medscape

Is anti-VEGF therapy more effective than the standard of care for retinal vein occlusions? In this video blog, David M. Brown, MD, reflects on the recent BRAVO ...

CF Patients at Higher Risk for Retinal Vein Occlusions, Case Report Says  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Post-marketing surveillance study of the safety of dexamethasone intra | OPTH  Dove Medical Press

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment ...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, ...

Global Vascular Endothelial Growth Factor B Market 2019 Alteogen Inc, CSL Ltd, Eli Lilly and Company, Formycon AG  World Industry Reports

The “Vascular Endothelial Growth Factor B Market” report contains wide-extending factual assessment for Vascular Endothelial Growth Factor B, which enables ...

Q3 2019 EPS Estimates for Clearside Biomedical Inc Increased by Wedbush (NASDAQ:CLSD)  Mayfield Recorder

Clearside Biomedical Inc (NASDAQ:CLSD) – Wedbush lifted their Q3 2019 earnings estimates for Clearside Biomedical in a note issued to investors on ...

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Bought by Harel Insurance Investments & Financial Services Ltd.  Riverton Roll

Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 104.3% during the ...

THERAPIX BIOSCI/S (NASDAQ:TRPX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) Head to Head Comparison  Mayfield Recorder

THERAPIX BIOSCI/S (NASDAQ:TRPX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment?

Clearside Biomedical (NASDAQ:CLSD) Downgraded by Needham & Company LLC to Hold  Mayfield Recorder

Needham & Company LLC downgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a buy rating to a hold rating in a report issued on Friday, August ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

DBV TECHNOLOGIE/S (NASDAQ:DBVT) versus Momenta Pharmaceuticals (NASDAQ:MNTA) Head-To-Head Contrast  Mayfield Recorder

DBV TECHNOLOGIE/S (NASDAQ:DBVT) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the superior ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Vascular Endothelial Growth Factor B Market Revenue, Status and Outlook 2018 to 2025  Newzy

The Vascular Endothelial Growth Factor B Market Size, Status And Forecast 2019-2025. The report provides information and the advancing Vascular Endothelial ...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the ...

Ohr Pharmaceutical Inc (NASDAQ:OHRP) Shorted Shares Increased 34.41% After Market Selling  The MAK Daily

The stock of Ohr Pharmaceutical Inc (NASDAQ:OHRP) registered an increase of 34.41% in short interest. OHRP's total short interest was 284000 shares in ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

EPS for Clearside Biomedical, Inc. (CLSD) Expected At $-0.37  The MAK Daily

Analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD) to report $-0.37 EPS on August, 14.They anticipate $0.28 EPS change or 43.08 % from last ...

Woman presents with bilateral eye pain and unilateral hyphema  Healio

Ocular Surgery News | A 64-year-old Hispanic woman presented to the emergency department with bilateral pain that started 2 days before presentation.

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

Roche reports very strong performance in the first half of 2019 – Outlook raised  GlobeNewswire

Basel, 25 July 2019. Group sales increase 9%1 at constant exchange rates and 8% in Swiss francs; Pharmaceuticals Division sales up 10%, driven mainly by ...

» Load more